FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1736348791> ?p ?o ?g. }

• W1736348791 endingPage "752" @default.
• W1736348791 startingPage "745" @default.
• W1736348791 abstract "What's known on the subject? and What does the study add? Receipt of androgen deprivation therapy (ADT) has been associated with an increased risk of skeletal-associated complications, such as a decrease in bone mineral density and an increase in fracture risk. Many men with pre-existing health conditions receive ADT as their primary treatment because they are considered to be inappropriate candidates for attempted curative treatments. However, several chronic health conditions, such as diabetes, rheumatoid disease and chronic liver disease, are strong predictors for osteoporosis and fractures. We undertook the present study aiming to quantify the impact of treating men with ADT who carry known risk factors for skeletal complications. Among these high-risk men, more than 58% develop at least one fracture after ADT within the 12 years of follow-up. Men who sustained a fracture within 48 months experienced an almost 40% higher risk of mortality than those who did not. Our findings suggest that treating men with a high fracture risk at baseline with long-term ADT may have serious adverse consequences. Objective To quantify the impact of androgen deprivation therapy (ADT) in men with a high baseline risk of skeletal complications and evaluate the risk of mortality after a fracture. Patients and Methods We studied 75 994 men, aged ≥66 years, with localized prostate cancer from the Surveillance, Epidemiology and End Results–Medicare linked data. Cox proportional hazard models were employed to evaluate the risk. Results Men with a high baseline risk of skeletal complications have a higher probability of receiving ADT than those with a low risk (52.1% vs 38.2%, P < 0.001). During the 12-year follow-up, more than 58% of men with a high risk and 38% of men with a low risk developed at least one fracture after ADT. The dose effect of ADT is stronger among men who received ADT only compared to those who received ADT with other treatments. In the high-risk group, the fracture rate increased by 19.9 per 1000 person-years (from 52.9 to 73.0 person-years) for men who did not receive ADT compared to those who received 18 or more doses of gonadotropin-releasing hormone agonist among men who received ADT only, and by 14.2 per 1000 person-years (from 45.2 to 59.4 person-years) among men who received ADT and other treatments. Men experiencing a fracture had a 1.38-fold higher overall mortality risk than those who did not (95% CI, 1.34–1.43). Conclusions Men with a high baseline risk of skeletal complications developed more fractures after ADT. The mortality risk is 40% higher after experiencing a fracture. Consideration of patient risk before prescribing ADT for long-term use may reduce both fracture risk and fracture-associated mortality." @default.
• W1736348791 created "2016-06-24" @default.
• W1736348791 creator A5005424988 @default.
• W1736348791 creator A5009692912 @default.
• W1736348791 creator A5012792790 @default.
• W1736348791 creator A5026667667 @default.
• W1736348791 creator A5044026355 @default.
• W1736348791 creator A5050736716 @default.
• W1736348791 date "2013-01-17" @default.
• W1736348791 modified "2023-10-12" @default.
• W1736348791 title "Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications" @default.
• W1736348791 cites W1964891491 @default.
• W1736348791 cites W1970232130 @default.
• W1736348791 cites W1992912488 @default.
• W1736348791 cites W1997732940 @default.
• W1736348791 cites W2000445173 @default.
• W1736348791 cites W2008795349 @default.
• W1736348791 cites W2061450074 @default.
• W1736348791 cites W2064222904 @default.
• W1736348791 cites W2065616395 @default.
• W1736348791 cites W2098998490 @default.
• W1736348791 cites W2122906075 @default.
• W1736348791 cites W2123318366 @default.
• W1736348791 cites W2137372444 @default.
• W1736348791 cites W2137704198 @default.
• W1736348791 cites W2140905531 @default.
• W1736348791 cites W2162514583 @default.
• W1736348791 cites W2164090407 @default.
• W1736348791 cites W2165948908 @default.
• W1736348791 cites W4250849363 @default.
• W1736348791 cites W4367435927 @default.
• W1736348791 doi "https://doi.org/10.1111/j.1464-410x.2012.11758.x" @default.
• W1736348791 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3625488" @default.
• W1736348791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24118960" @default.
• W1736348791 hasPublicationYear "2013" @default.
• W1736348791 type Work @default.
• W1736348791 sameAs 1736348791 @default.
• W1736348791 citedByCount "54" @default.
• W1736348791 countsByYear W17363487912013 @default.
• W1736348791 countsByYear W17363487912014 @default.
• W1736348791 countsByYear W17363487912015 @default.
• W1736348791 countsByYear W17363487912016 @default.
• W1736348791 countsByYear W17363487912017 @default.
• W1736348791 countsByYear W17363487912018 @default.
• W1736348791 countsByYear W17363487912019 @default.
• W1736348791 countsByYear W17363487912020 @default.
• W1736348791 countsByYear W17363487912021 @default.
• W1736348791 countsByYear W17363487912022 @default.
• W1736348791 countsByYear W17363487912023 @default.
• W1736348791 crossrefType "journal-article" @default.
• W1736348791 hasAuthorship W1736348791A5005424988 @default.
• W1736348791 hasAuthorship W1736348791A5009692912 @default.
• W1736348791 hasAuthorship W1736348791A5012792790 @default.
• W1736348791 hasAuthorship W1736348791A5026667667 @default.
• W1736348791 hasAuthorship W1736348791A5044026355 @default.
• W1736348791 hasAuthorship W1736348791A5050736716 @default.
• W1736348791 hasBestOaLocation W17363487911 @default.
• W1736348791 hasConcept C107130276 @default.
• W1736348791 hasConcept C121608353 @default.
• W1736348791 hasConcept C126322002 @default.
• W1736348791 hasConcept C141071460 @default.
• W1736348791 hasConcept C1862650 @default.
• W1736348791 hasConcept C197934379 @default.
• W1736348791 hasConcept C207103383 @default.
• W1736348791 hasConcept C2776541429 @default.
• W1736348791 hasConcept C2777899217 @default.
• W1736348791 hasConcept C2779134260 @default.
• W1736348791 hasConcept C2780192828 @default.
• W1736348791 hasConcept C44249647 @default.
• W1736348791 hasConcept C50382708 @default.
• W1736348791 hasConcept C71924100 @default.
• W1736348791 hasConceptScore W1736348791C107130276 @default.
• W1736348791 hasConceptScore W1736348791C121608353 @default.
• W1736348791 hasConceptScore W1736348791C126322002 @default.
• W1736348791 hasConceptScore W1736348791C141071460 @default.
• W1736348791 hasConceptScore W1736348791C1862650 @default.
• W1736348791 hasConceptScore W1736348791C197934379 @default.
• W1736348791 hasConceptScore W1736348791C207103383 @default.
• W1736348791 hasConceptScore W1736348791C2776541429 @default.
• W1736348791 hasConceptScore W1736348791C2777899217 @default.
• W1736348791 hasConceptScore W1736348791C2779134260 @default.
• W1736348791 hasConceptScore W1736348791C2780192828 @default.
• W1736348791 hasConceptScore W1736348791C44249647 @default.
• W1736348791 hasConceptScore W1736348791C50382708 @default.
• W1736348791 hasConceptScore W1736348791C71924100 @default.
• W1736348791 hasIssue "5" @default.
• W1736348791 hasLocation W17363487911 @default.
• W1736348791 hasLocation W17363487912 @default.
• W1736348791 hasLocation W17363487913 @default.
• W1736348791 hasLocation W17363487914 @default.
• W1736348791 hasOpenAccess W1736348791 @default.
• W1736348791 hasPrimaryLocation W17363487911 @default.
• W1736348791 hasRelatedWork W1963763301 @default.
• W1736348791 hasRelatedWork W2035098213 @default.
• W1736348791 hasRelatedWork W2728894889 @default.
• W1736348791 hasRelatedWork W2753537866 @default.
• W1736348791 hasRelatedWork W2896276799 @default.
• W1736348791 hasRelatedWork W2915731681 @default.

• next